Skip to content
Investing

Novavax Investor Profile: Sanofi Royalties, the Matrix-M Adjuvant and $627m of Cash

Novavax now earns most of its money from partners led by Sanofi. It ended September with $627m of cash and $292.1m of long-term debt; its numbers, milestones, risks and dates to watch.

Novavax's white headquarters building in Gaithersburg, Maryland, with the Novavax name on the facade under a cloudy blue sky.
Photo: Toriino7 / Wikimedia Commons, CC BY 4.0

Novavax, the Maryland vaccine developer, has turned itself into a company that earns most of its money from partners, led by Sanofi, which now sells its Covid vaccine. It ended September with $627m of cash and investments and $292.1m of long-term debt, and it has raised its 2026 revenue outlook after a $125m milestone. It is still losing money, and much of its future income depends on Sanofi.

What Novavax does

Novavax is based in Gaithersburg, Maryland, and its shares trade on Nasdaq as NVAX. It develops protein-based vaccines. Its two main assets are Nuvaxovid, its Covid vaccine, and Matrix-M, an adjuvant that boosts the immune response to vaccines and can be licensed to other companies.

In May 2024 Novavax signed an agreement with Sanofi. Sanofi now sells Nuvaxovid and pays Novavax royalties on its global sales, can develop combined flu and Covid vaccines that use it, and can create new vaccines with Matrix-M. Takeda sells the vaccine in Japan, and the Serum Institute of India co-formulates and fills it.

An updated version of Nuvaxovid, matched to the XFG Covid variant, was approved in the US, the EU and Japan in August, and Sanofi and Takeda began selling it for the 2026-2027 season. In its own pipeline, Novavax expects a vaccine candidate against C. difficile bacteria to enter clinical trials as early as 2027, after presenting early laboratory data in September. Several studies of Matrix-M, run by Novavax and by partners in infectious disease and cancer, are under way and could lead to further licensing deals.

Novavax: share price, chart and news

A Novavax scientist in a lab coat, face mask, goggles and gloves working at laboratory equipment in Gaithersburg, Maryland, during a September 2020 visit by the state governor.
A Novavax scientist in a lab coat, face mask, goggles and gloves working at laboratory equipment in Gaithersburg, Maryland, during a September 2020 visit by the state governor. Photo: Maryland GovPics / Wikimedia Commons, CC BY 2.0

How the Sanofi deal pays

StreamWhat Novavax can earnStatus
Nuvaxovid milestonesUp to $350m$75m still to come on completion of the technology transfer, expected mid-2027
Nuvaxovid royaltiesHigh-teens to low-twenties percent of Sanofi's net salesPayable on Sanofi's sales, which began this season
Flu and Covid combination milestonesUp to $350m$125m earned in October 2026; $225m on a US launch
Combination royaltiesHigh-single-digit to sub-teens percentOnly after launch
New Matrix-M vaccinesUp to $200m in milestones each for the first four, plus mid-single-digit royaltiesDepends on Sanofi's programmes

The $125m payment was triggered when Sanofi dosed the fifth patient in a Phase 3 trial in Europe of Nuvaxovid given with its high-dose flu vaccine in adults aged 60 and over. Sanofi intends to start a US Phase 3 trial in 2027. Novavax says the partnership has brought in more than $1bn so far. Takeda pays annual milestones and mid-to-high-teens percentage royalties in Japan.

The latest numbers

MeasureQ3 2026Q3 2025Nine months 2026Nine months 2025
Total revenue$68.3m$70.4m$264.5m$976.3m
Product sales$25.7m$13.4m$86.7m$645.8m
Research and development$52.4m$98.3m$218.6m$266.4m
Selling, general and administrative$23.6m$31.7m$79.1m$123.4m
Net income (loss)-$31.4m-$202.4m-$94.3m$422.8m

Revenue has fallen sharply from last year's levels, while spending has been cut as Sanofi took over selling the vaccine and seasonal strain-change work shrank. Research reimbursements from Sanofi are nearing their end, which cut licensing income in the third quarter.

Partner income in the quarter came from Sanofi ($19m), Takeda ($7m), the Serum Institute ($5m) and other partners ($11m). The quarter also included $11m of non-cash deferred royalty income linked to earlier Nuvaxovid sales by SK bioscience. On an adjusted basis, which strips out some non-cash items, research spending was $48.7m, down 7% from a year earlier.

For 2026, Novavax now expects adjusted total revenue of $385m to $415m, up from $235m to $275m, with the $125m milestone included. It expects combined research and administrative costs of $375m to $395m.

Cash, debt and shares

At 30 September 2026

  • $627m cash, cash equivalents, marketable securities and restricted cash
  • $292.1m long-term debt, net of issuance costs
  • 165.0m shares outstanding on 31 October

Cash fell from $751m at the end of 2025, and operations used $199.5m in the first nine months. The debt is made up of $26.5m of 5.00% convertible notes due 2027, $225.0m of 4.625% convertible notes due 2031 and $50.0m drawn under a loan from MidCap Financial of up to $330.0m. That loan is secured on substantially all of Novavax's assets, carries a floating rate that stood at 8.7% at the end of September, and requires the company to hold at least $100m of unrestricted cash at all times. Repaying it early costs a premium of 1% to 3%, plus a 2.75% exit fee.

Shareholders' equity was negative at $216.9m. Management expects to have enough capital for at least a year from the date of the accounts.

Risks and what to watch

Main risks

  • Reliance on Sanofi. The largest future payments depend on Sanofi's trials, approvals and sales.
  • Falling Covid demand. Nine-month revenue fell by almost three quarters from a year earlier.
  • Refund and partner liabilities. Up to $92.5m of deferred revenue under an Australian supply deal could become refundable if an updated vaccine is not approved and delivered in time, and Novavax is awaiting a decision from the Australian regulator. It also carries $210m of liabilities to Gavi.
  • Key supplier. It depends heavily on the Serum Institute of India to co-formulate, fill and finish its Covid vaccine.
  • Debt. Secured debt carries a minimum-cash covenant, and convertible notes fall due in 2027 and 2031.
WhenWhat
Q4 2026 resultsFirst results to include the $125m Sanofi milestone, earned in October
2026-2027 seasonRoyalties from Sanofi and Takeda sales of the updated Nuvaxovid
Mid-2027Expected completion of the technology transfer to Sanofi and a $75m milestone
2027Planned start of Sanofi's US Phase 3 combination vaccine trial
2027C. difficile vaccine candidate could enter the clinic
Not dated$225m milestone on a US launch of a combined flu and Covid vaccine

Sources

Related stories

Markets

Novavax Lifts Its 2026 Revenue Outlook to as Much as $415m on a $125m Sanofi Milestone

Novavax raised its 2026 revenue guidance to $385m to $415m after a $125m Sanofi milestone, while third-quarter revenue slipped 3% to $68.3m and its net loss narrowed to $31.4m.

Investing

Viking Therapeutics Investor Profile: VK2735, Two Phase 3 Programmes and $960m of Cash

Viking Therapeutics is testing obesity drug VK2735 in Phase 3 as a weekly injection and a daily pill. It had $960m of cash at the end of September but lost $183.2m in the third…

Investing

Kraig Biocraft Laboratories Profile: Spider Silk From Silkworms, Still Before Revenue

Kraig Biocraft Laboratories breeds silkworms that spin spider silk and farms them in Vietnam. It has begun shipping yarn but reported no revenue in the first half and carries a…

Investing

Boss Energy Profile: Honeymoon, Alta Mesa and a Year of Transition for the Uranium Producer

Boss Energy mines uranium at Honeymoon in South Australia and owns 30% of Alta Mesa in Texas. It has no debt and a large stockpile, but output falls this year as it changes mining…

Investing

Aya Gold & Silver Corrects Q3 Cash Costs to $14.28 an Ounce After Silver Double Count

Aya Gold & Silver refiled its Q3 MD&A after silver in transit was deducted twice. Zgounder ounces sold rise to 1,392,478 and cash costs fall to $14.28 from $15.51. Revenue and…

Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

Investing

Red Cat Withdraws Its $150m to $180m 2026 Revenue Target After $11.8m Third Quarter

Red Cat Holdings has withdrawn its $150m to $180m revenue target for 2026 after third-quarter sales of $11.8m, blaming slower defence funding. Its quarterly net loss more than…

Investing

Berkshire Reveals $689m Bending Spoons Stake, Doubles Lennar and Trims Bank of America Again

Berkshire Hathaway's third-quarter 13F shows a new Bending Spoons stake worth $689m, a doubled Lennar holding and 27.5 million more Bank of America shares sold, while Apple stayed…